Showing results (2091-2100 of 2,271) with videos related to
Sort By:
Pageof 228
Nature Communications|January 2, 2025
Enhanced motivated behavior mediated by pharmacological targeting of the FGF14/Nav1.6 complex in nucleus accumbens neuronsNolan M Dvorak, Paul A Wadsworth, Guillermo Aquino-Miranda, et al.Journal for Immunotherapy of Cancer|November 27, 2020
Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4Lisa A Marshall, Sachie Marubayashi, Aparna Jorapur, et al.Advanced Energy Materials|October 19, 2020
Influence of Polymer Aggregation and Liquid Immiscibility on Morphology Tuning by Varying Composition in PffBT4T-2DT/Non-Fullerene Organic Solar CellsZeinab Hamid, Andrew Wadsworth, Elham Rezasoltani, et al.Physical Review Letters|November 13, 2003
Evidence for a new type of shears mechanism in 106CdA J Simons, R Wadsworth, D G Jenkins, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 20, 2011
An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28David R Owen, Astrid J Yeo, Roger N Gunn, et al.Nature Materials|November 22, 2016
Reducing the efficiency-stability-cost gap of organic photovoltaics with highly efficient and stable small molecule acceptor ternary solar cellsDerya Baran, Raja Shahid Ashraf, David A Hanifi, et al.Bioorganic & Medicinal Chemistry Letters|March 5, 2008
Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisationJason Witherington, Lee Abberley, Michael A Briggs, et al.Diabetes|February 9, 2012
Interbirth interval is associated with childhood type 1 diabetes riskChris R Cardwell, Jannet Svensson, Thomas Waldhoer, et al.Bioorganic & Medicinal Chemistry Letters|March 16, 2013
Exploration of the structure-activity relationship of a novel tetracyclic class of TSPO ligands-potential novel positron emitting tomography imaging agentsDennis O'Shea, Rabia Ahmad, Erik Årstad, et al.BMC Cancer|September 13, 2013
Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenograftsSherrill L Macura, Jeremy L Steinbacher, Maximilian B Macpherson, et al.Pageof 228